To answer the question of how commonly the mTOR, cell cycle and PI3K pathways are involved in regulation of sensitivity to anti-cancer compounds with similar mechanism of action as Nutlin-3 we intersected the data on sensitivity to the MDM2 inhibitor (AMGMDS3 compound) described in the paper Saiki et al. [30] with the biggest resource of gene expression data on various cancer cell lines – the CCLE (Cancer Cell Line Encyclopedia) [33, 34]. The gene discussed is MTOR; the disease is cancer.